Metactive Medical Inc., an Olathe, Kan.-based early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, closed on $2m of additional Series A financing.
The round was led by existing investor Kansas Bioscience Authority (KBA). In addition to the funding, David Ferrera, currently President and Chief Technology Officer of Blockade Medical, joined Metactive’s board of directors.
The company, which has raised to date to $7m, intends to use the funds to continue the development of its novel embolic devices.
Led by F. Nicholas Franano, MD, President and CEO, Metactive is developing novel endovascular medical devices for the treatment of neurovascular and peripheral vascular diseases. Its first products enable precise occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform.